Literature DB >> 16314830

Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization.

C Colin1, N Baeza, C Bartoli, F Fina, N Eudes, I Nanni, P-M Martin, L Ouafik, D Figarella-Branger.   

Abstract

Glioblastoma (GBM) is a highly malignant glioma, which has the propensity to infiltrate throughout the brain in contrast to pilocytic astrocytoma (PA) of the posterior fossa, which does not spread and can be cured by surgery. We have used Suppression Subtractive Hybridization to define markers that better delineate the molecular basis of brain invasion and distinguish these tumor groups. We have identified 106 genes expressed in PA versus GBM and 80 genes expressed in GBM versus PA. Subsequent analysis identified a subset of 20 transcripts showing a common differential expression pattern for the two groups. GBM differs from PA by the expression of five genes involved in invasion and angiogenesis: fibronectin, osteopontin, chitinase-3-like-1 (YKL-40), keratoepithelin and fibromodulin. PA differs from GBM by the expression of genes related to metabolism (apolipoprotein D), proteolysis (protease-serine-11), receptor and signal transduction (PLEKHB1 for Pleckstrin-Homology-domain-containing-protein-family-B-member-1), transcription/translation (eukaryotic-translation-elongation-factor-1-alpha1) processes and cell adhesion (SPOCK1 for SPARC/Osteonectin-CWCV-kazal-like-domains-proteoglycan). The expression of these genes was confirmed by real-time quantitative RT-PCR and immunohistochemistry. This study highlights the crucial role of brain invasion in GBM and identifies specific molecules involved in this process. In addition, it offers a restricted list of markers that accurately distinguish PA from GBM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16314830     DOI: 10.1038/sj.onc.1209305

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Cells with intense EGFR staining and a high nuclear to cytoplasmic ratio are specific for infiltrative glioma: a useful marker in neuropathological practice.

Authors:  Fanny Burel-Vandenbos; Laurent Turchi; Maxime Benchetrit; Eric Fontas; Zoe Pedeutour; Valérie Rigau; Fabien Almairac; Damien Ambrosetti; Jean-François Michiels; Thierry Virolle
Journal:  Neuro Oncol       Date:  2013-08-09       Impact factor: 12.300

2.  Differentially Expressed Long Non-Coding RNAs Were Predicted to Be Involved in the Control of Signaling Pathways in Pediatric Astrocytoma.

Authors:  Ruth Ruiz Esparza-Garrido; Juan Manuel Rodríguez-Corona; Javier Enrique López-Aguilar; Marco Antonio Rodríguez-Florido; Ana Claudia Velázquez-Wong; Rubí Viedma-Rodríguez; Fabio Salamanca-Gómez; Miguel Ángel Velázquez-Flores
Journal:  Mol Neurobiol       Date:  2016-10-13       Impact factor: 5.590

3.  SPOCK1 is upregulated in recurrent glioblastoma and contributes to metastasis and Temozolomide resistance.

Authors:  Fengbo Yu; Guihong Li; Junxia Gao; Yuxue Sun; Pengfei Liu; Haijun Gao; Peiwen Li; Ting Lei; Yong Chen; Ye Cheng; Xiao Zhai; Arash J Sayari; Haiyan Huang; Qingchun Mu
Journal:  Cell Prolif       Date:  2016-02-28       Impact factor: 6.831

4.  Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.

Authors:  Camilla Bjørnbak; Christian B Brøchner; Lars A Larsen; Julia S Johansen; Kjeld Møllgård
Journal:  J Histochem Cytochem       Date:  2014-03-04       Impact factor: 2.479

5.  More than skin deep: connecting melanocyte pigmentation and angiogenic diseases.

Authors:  Christopher D Kontos
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

6.  Invariant delineation of nuclear architecture in glioblastoma multiforme for clinical and molecular association.

Authors:  Hang Chang; Ju Han; Alexander Borowsky; Leandro Loss; Joe W Gray; Paul T Spellman; Bahram Parvin
Journal:  IEEE Trans Med Imaging       Date:  2012-12-04       Impact factor: 10.048

7.  Osteopontin regulates human glioma cell invasiveness and tumor growth in mice.

Authors:  Hsun-Jin Jan; Chin-Cheng Lee; Yung-Luen Shih; Dueng-Yuan Hueng; Hsin-I Ma; Jing-Huei Lai; Hen-Wei Wei; Horng-Mo Lee
Journal:  Neuro Oncol       Date:  2009-12-23       Impact factor: 12.300

8.  Two novel VHL targets, TGFBI (BIGH3) and its transactivator KLF10, are up-regulated in renal clear cell carcinoma and other tumors.

Authors:  Sergey V Ivanov; Alla V Ivanova; Konstantin Salnikow; Olga Timofeeva; Malayannan Subramaniam; Michael I Lerman
Journal:  Biochem Biophys Res Commun       Date:  2008-03-24       Impact factor: 3.575

9.  Correlation between osteopontin protein expression and histological grade of astrocytomas.

Authors:  H Toy; O Yavas; O Eren; M Genc; C Yavas
Journal:  Pathol Oncol Res       Date:  2008-12-02       Impact factor: 3.201

10.  Thrombin-cleaved fragments of osteopontin are overexpressed in malignant glial tumors and provide a molecular niche with survival advantage.

Authors:  Yasuto Yamaguchi; Zhifei Shao; Shadi Sharif; Xiao-Yan Du; Timothy Myles; Milton Merchant; Griffith Harsh; Michael Glantz; Lawrence Recht; John Morser; Lawrence L K Leung
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.